Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients recently diagnosed with mild to moderate cases of COVID-19.  In June, the company began a trial delivering either placebo or an antibody, called LY-CoV555, to 452 patients. These were patients with mild or moderate symptoms who hadContinue Reading

Despite a lack of scientific studies on its efficacy for Covid-19, interest in the treatment has surged alongside case numbers. The demand for convalescent plasma continues to rise and blood collection organizations are struggling to keep up. One way they have increased the supply of appropriate plasma is to testContinue Reading

Kaiser Health news clarifies the current situation about convalescent plasma. The treatment has been re-approved for emergency use by the FDA. However, the way in which it was re-approved has been controversial. The main concern from experts about the clinical trials of this treatment is that they do not useContinue Reading

Despite the wave of criticism that has followed the U.S. Food and Drug Administration’s emergency approval of convalescent plasma to treat COVID-19 patients, infectious disease experts say the therapy remains promising. Medical Express interviewed physicians running trials studying convalescent plasma treatments in the United States. I cannot think of oneContinue Reading